What is the Generic Name for Cosentyx?

Secukinumab, sold under the brand name Cosentyx, is a human IgG1κ monoclonal antibody that binds to the interleukin-17A protein and is marketed by Novartis for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis. This article provides an in-depth look at the product, its generic name, and patient assistance programs to support those in need of this medication.

Understanding Cosentyx

Secukinumab, also known as Cosentyx, is a medication that inhibits interleukin-17A, a member of the cytokine family. By blocking this protein, Cosentyx helps reduce inflammation and manage the symptoms of these chronic conditions. The medication is administered via subcutaneous injection and is available in various dosage strengths.

The Generic Name: Secukinumab

While Cosentyx is the brand name under which Secukinumab is marketed, the generic name of this medication is Secukinumab. This generic name is recognized and used by various healthcare providers and regulatory bodies around the world. The use of a generic name allows for clear communication and documentation in medical records and facilitates research and development efforts.

Novartis Patient Assistance Program: CosentyxConnect

Novartis, the manufacturer of Cosentyx, understands that cost can be a barrier to accessing essential medications. To provide support, they offer a Patient Assistance Program called CosentyxConnect. This program is designed to help patients who cannot afford the medication by working closely with their healthcare providers to ensure they have access to the treatment they need.

Enrolling in CosentyxConnect

Patients interested in enrolling in the CosentyxConnect program can contact Novartis Pharmaceuticals through their Patient Assistance Foundation Enrollment in the United States. The process begins with a conversation with your medical doctor, who will help you understand the eligibility criteria and guide you through the application process.

Additional Resources

For more information about the CosentyxConnect program, including eligibility requirements and application details, visit the official Novartis website. Additionally, you can find resources on managing psoriasis, ankylosing spondylitis, and psoriatic arthritis. These resources may include patient education materials, support groups, and information about lifestyle changes that can help improve your condition.

Conclusion

Secukinumab, or Cosentyx, is a crucial medication for treating psoriasis, ankylosing spondylitis, and psoriatic arthritis. With its generic name, Secukinumab, healthcare providers can easily refer to it in medical contexts. For those who need financial assistance, the CosentyxConnect program offers support. By understanding the generic name and the available support programs, patients can make informed decisions about their treatment options.

Note: Always consult with a healthcare provider for personalized medical advice and information.